Celldex Therapeutics, Inc. Forecast, price target & analysts
Celldex Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
Celldex Therapeutics, Inc. Classifications & Recommendation
Celldex Therapeutics, Inc. Price Target
| Target Price | $57.12 |
| Price | $31.65 |
| Potential |
80.47%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Celldex Therapeutics, Inc. 2027 .
The average Celldex Therapeutics, Inc. target price is $57.12.
This is
80.47%
register free of charge
$105.00
231.75%
register free of charge
$38.38
21.26%
register free of charge
|
|
| A rating was issued by 22 analysts: 20 Analysts recommend Celldex Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Celldex Therapeutics, Inc. stock has an average upside potential 2027 of
80.47%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 1.55 | 1.63 |
| 77.92% | 4.90% | |
| EBITDA Margin | -18,321.94% | -20,640.08% |
| 570.24% | 12.65% | |
| Net Margin | -16,694.19% | -20,504.27% |
| 642.39% | 22.82% |
14 Analysts have issued a sales forecast Celldex Therapeutics, Inc. 2026 . The average Celldex Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Celldex Therapeutics, Inc. EBITDA forecast 2026. The average Celldex Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 Celldex Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average Celldex Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.90 | -4.25 |
| 59.18% | 8.97% | |
| P/E | negative | |
| EV/Sales | 1,087.25 |
15 Analysts have issued a Celldex Therapeutics, Inc. forecast for earnings per share. The average Celldex Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Celldex Therapeutics, Inc....
Current Celldex Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Sep 23 2026 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Sep 23 2026 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Sep 22 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 22 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Sep 10 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Sep 23 2026 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Sep 23 2026 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Sep 22 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 22 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Sep 10 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 07 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
